{
    "nct_id": "NCT03899792",
    "official_title": "A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors",
    "inclusion_criteria": "* Advanced or metastatic solid or primary CNS tumor which has failed standard of care therapies\n* Evidence of an activating RET gene alteration in the tumor and/or blood\n* Measurable or non-measurable disease\n* Karnofsky (participants 16 years and older) or Lansky (participants younger than 16) performance score of at least 50\n* Participant with primary CNS tumors or cerebral metastases must be neurologically stable for 7 days prior and must not have required increasing doses of steroids within the last 7 days\n* Adequate hematologic, hepatic and renal function.\n* Ability to receive study drug therapy orally or via gastric access\n* Willingness of men and women of reproductive potential to observe conventional and effective birth control\nHealthy volunteers allowed\nMust have minimum age of 6 Months\nMust have maximum age of 21 Years",
    "exclusion_criteria": "* Major surgery within two weeks prior to planned start of LOXO-292\n* Clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of LOXO-292\n* Active uncontrolled systemic bacterial, viral, fungal or parasitic infection\n* Clinically significant active malabsorption syndrome\n* Pregnancy or lactation\n* Uncontrolled symptomatic hyperthyroidism or hypothyroidism (i.e. the participant required a modification to current thyroid medication in the 7 days before start of LOXO-292)\n* Uncontrolled symptomatic hypercalcemia or hypocalcemia\n* Known hypersensitivity to any of the components of the investigational agent, LOXO-292 or Ora-Sweet® SF and OraPlus®, for participants who will receive LOXO-292 suspension\n* Prior treatment with a selective RET inhibitor(s) (including investigational selective RET inhibitor[s])",
    "miscellaneous_criteria": ""
}